The biomedical company Xintela announced that it has completed its second of three dose levels in its phase I/IIa trial testing the efficacy of XSTEM—which consists of allogenic integrin α10β1–selected mesenchymal stem cells—in patients with knee osteoarthritis. In the new study, the researchers included 54 patients with knee osteoarthritis and injected XSTEM directly into the knee joint. The patients will have follow-up appointments every 6 months for 18 months to examine whether the treatment is safe and to monitor indicators of efficacy such as decreased joint cartilage wear, cartilage regeneration, and greater joint functionality. The researchers noted that once the safety of the treatment has been established, they will commence the third dose level.
May 25, 2023